These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30813952)

  • 1. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
    Redenšek S; Flisar D; Kojović M; Kramberger MG; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
    J Neuroinflammation; 2019 Feb; 16(1):50. PubMed ID: 30813952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Genetic Polymorphisms in Oxidative Stress and Inflammation Pathways with Glaucoma Risk and Phenotype.
    Atanasovska Velkovska M; Goričar K; Blagus T; Dolžan V; Cvenkel B
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33803434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome.
    Herman R; Jensterle M; Janež A; Goričar K; Dolžan V
    Metabolites; 2020 Oct; 10(11):. PubMed ID: 33138337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):496-504. PubMed ID: 32710539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Flisar D; Kojović M; Gregorič Kramberger M; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
    Front Pharmacol; 2019; 10():8. PubMed ID: 30745869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Polymorphisms, Gene-Gene Interactions and Neurologic Sequelae at Two Years Follow-Up in Newborns with Hypoxic-Ischemic Encephalopathy Treated with Hypothermia.
    Esih K; Goričar K; Soltirovska-Šalamon A; Dolžan V; Rener-Primec Z
    Antioxidants (Basel); 2021 Sep; 10(9):. PubMed ID: 34573127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superoxide dismutase coding of gene polymorphisms associated with susceptibility to Parkinson's disease.
    Liu C; Fang J; Liu W
    J Integr Neurosci; 2019 Sep; 18(3):299-303. PubMed ID: 31601079
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Esih K; Goričar K; Rener-Primec Z; Dolžan V; Soltirovska-Šalamon A
    Antioxidants (Basel); 2021 Jan; 10(1):. PubMed ID: 33445495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.
    Santos-Lobato BL; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
    Nitric Oxide; 2018 Apr; 74():86-90. PubMed ID: 28602747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation of the genes encoding antioxidant enzymes SOD2 (rs4880), GPX1 (rs1050450), and CAT (rs1001179) and susceptibility to male infertility: a genetic association study and in silico analysis.
    Fallah F; Colagar AH; Saleh HA; Ranjbar M
    Environ Sci Pollut Res Int; 2023 Aug; 30(36):86412-86424. PubMed ID: 37405601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and Oxidative Stress Gene Variability in Retinal Detachment Patients with and without Proliferative Vitreoretinopathy.
    Lumi X; Confalonieri F; Ravnik-Glavač M; Goričar K; Blagus T; Dolžan V; Petrovski G; Hawlina M; Glavač D
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Front Genet; 2019; 10():461. PubMed ID: 31156712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Variability of Inflammation and Oxidative Stress Genes Affects Onset, Progression of the Disease and Survival of Patients with Amyotrophic Lateral Sclerosis.
    Ravnik-Glavač M; Goričar K; Vogrinc D; Koritnik B; Lavrenčič JG; Glavač D; Dolžan V
    Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between epidermal growth factor receptor gene polymorphisms and susceptibility to Parkinson's disease.
    Jin J; Xue L; Bai X; Zhang X; Tian Q; Xie A
    Neurosci Lett; 2020 Sep; 736():135273. PubMed ID: 32712352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.